Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
about
TFP5 prevents 1-methyl-4-phenyl pyridine ion-induced neurotoxicity in mouse cortical neurons.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.Early versus delayed initiation of pharmacotherapy in Parkinson's disease.
P2860
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drugs and drug delivery in PD: ...... pramipexole prolonged-release.
@en
Drugs and drug delivery in PD: ...... pramipexole prolonged-release.
@nl
type
label
Drugs and drug delivery in PD: ...... pramipexole prolonged-release.
@en
Drugs and drug delivery in PD: ...... pramipexole prolonged-release.
@nl
prefLabel
Drugs and drug delivery in PD: ...... pramipexole prolonged-release.
@en
Drugs and drug delivery in PD: ...... pramipexole prolonged-release.
@nl
P2860
P1476
Drugs and drug delivery in PD: ...... pramipexole prolonged-release.
@en
P2093
P2860
P356
10.1111/J.1468-1331.2010.03326.X
P478
18 Suppl 1
P577
2011-03-01T00:00:00Z